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Abstract
Poly(ethylene glycol)-lipid (PEG-lipid) conjugates are widely used in the field of liposomal drug delivery to provide a
polymer coat that can confer favorable pharmacokinetic characteristics on particles in the circulation. More recently these
lipids have been employed as an essential component in the self-assembly of cationic and neutral lipids with polynucleic acids
to form small, stable lipid/DNA complexes that exhibit long circulation times in vivo and accumulate at sites of disease.
However, the presence of a steric barrier lipid might be expected to inhibit the transfection activity of lipid/DNA complexes
by reducing particle-membrane contact. In this study we examine what effect varying the size of the hydrophobic anchor and
hydrophilic head group of PEG-lipids has on both gene and antisense delivery into cells in culture. Lipid/DNA complexes
were made using unilamellar vesicles composed of 5 mole% PEG-lipids in combination with equimolar dioleoylphos-
phatidylethanolamine and the cationic lipid dioleyldimethylammonium chloride. Using HeLa and HepG2 cells we show that
under the conditions employed PEG-lipids had a minimal effect on the binding and subsequent endocytosis of lipid/DNA
complexes but they severely inhibited active gene transfer and the endosomal release of antisense oligodeoxynucleotides into
the cytoplasm. Decreasing the size of the hydrophobic anchor or the size of the grafted hydrophilic PEG moiety enhanced
DNA transfer by the complexes. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Poly(ethylene glycol)-lipid (PEG-lipid) conjugates
are now a common component of lipid-based drug
delivery systems. When incorporated into conven-
tional liposomes, they provide a steric barrier at
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monium chloride; RhoPE, 1,2-dioleoyl-glycero-3-phosphoethanolamine-N-(lissamine rhodamine L sulfonyl) ; PBS, phosphate bu¡ered
saline; DMEM, Dulbecco’s modi¢ed Eagle’s medium; MEM, minimum essential medium; DNA, deoxyribonucleic acid; ODN, phos-
phorothioate oligonucleotide; FITC-ODN, ODN labeled with £uorescein at the 5P end; PEG, poly(ethylene glycol); Gal-PEG(n)-DSPE,
galactosylcerebroside-PEG(n)-DSPE, where n = M.Wt. of PEG; PEG(2000)-CerC8, 1-O-[2P-(g-methoxypolyethyleneglycol)succinoyl]-
2-N-octanoylsphingosine; PEG(2000)-CerC14, 1-O-[2P-(g-methoxypolyethyleneglycol)succinoyl]-2-N-myristoylsphingosine; PEG(2000)-
CerC20, 1-O-[2P-(g-methoxypolyethyleneglycol)succinoyl]-2-N-arachidoylsphingosine
* Corresponding author. Fax: 604-419-3201. E-mail address: bmui@inexpharm.com (B. Mui).
BBAMEM 78162 11-12-01 Cyaan Magenta Geel Zwart
Biochimica et Biophysica Acta 1558 (2002) 1^13
www.bba-direct.com
the liposomal surface that inhibits opsonization,
therefore extending the residence time of liposomes
in the blood [1,40]. For liposomes containing drug
this maximizes drug delivery to sites of disease where
pores and gaps in the endothelium allow carriers to
undergo passive extravasation and accumulation in
both tumor and in£amed tissues [12,14]. PEG-lipids
have also been utilized in the development of tar-
geted liposomes. Low molecular weight ligands
such as galactose [32] and folic acid [15] have been
conjugated to the end of the polymer to increase
binding of PEG-coated drug delivery systems to
cell surface receptors. Antibodies and antibody frag-
ments have also been covalently linked to liposomes
via PEG-lipids to form immunoliposomes that
bind to cells displaying the appropriate antigens
[17,11].
Yet another application for PEG-lipids is in the
formulation of DNA with cationic lipid vesicles to
form lipid-based antisense and gene delivery systems
suitable for systemic administration [31,41]. One of
the most common lipid-based carriers of polynucleo-
tides are lipid/DNA complexes, sometimes referred
to as lipoplexes [5], formed by mixing preformed cat-
ionic vesicles with DNA at precise +/3 charge ratios.
These systems are used extensively as tools for the
intracellular delivery of gene constructs, antisense
oligodeoxynucleotides (ODN) and ribozymes to cells
in culture [23]. Lipid/DNA complexes can also medi-
ate gene transfer in vivo [23,24,37] ; however, their
inherent instability, rapid clearance, large particle
size and toxicity limit their use as a clinically viable
intravenous delivery system for DNA. More recently,
lipid-based formulations with greatly improved phar-
macokinetic characteristics have been developed for
plasmids [6,41,46], antisense ODN and ribozymes
[31] in which PEG-lipids play an active role in the
formulation process by inhibiting excessive aggrega-
tion and fusion during the critical self-assembly
phase when cationic lipids associate with anionic
DNA. These delivery systems are stable, homogene-
ous particles with diameters on the order of 100 nm
that completely protect their polynucleic acid pay-
loads from nuclease degradation in plasma. Further-
more, they exhibit circulation lifetimes that enable
intact plasmid, antisense and ribozyme molecules to
accumulate at distal sites following systemic admin-
istration.
However, in order for lipid-based DNA delivery
systems to successfully perturb endosomal mem-
branes and release nucleic acid into the cytoplasm,
exogenous lipid must be introduced into the host
membrane [39,23]. This occurs through lipid mixing
or fusion between the target membrane and lipid/
DNA complexes when the latter possesses the appro-
priate lipid composition and is in su⁄ciently close
apposition to the cell membrane. By de¢nition a ster-
ic barrier would be expected to inhibit these process-
es and therefore reduce transfection activity. In this
study we have employed a series of PEG-lipid con-
jugates in which the size of the polymer head group
and amide chain length of the hydrophobic anchors
have been varied to determine what e¡ect this has on
DNA transfer into cultured cells.
2. Methods
2.1. Materials
HepG2 cells were obtained from ATCC (Rock-
ville, MD, USA) and HeLa cells were a generous
gift from Dr. M. Hayden at the University of British
Columbia (Vancouver, BC, Canada). Minimal essen-
tial medium (MEM) and Dulbecco’s modi¢ed Ea-
gle’s medium (DMEM) were purchased from Stem
Cell Technologies (Vancouver, BC, Canada), fetal
bovine serum (FBS) and the antibiotic G418 were
from Gibco (Burlington, ON, Canada). The plasmid
used to generate the stably transfected HeLa cell line
contains the luciferase gene cloned into the tIRE-
SNeo plasmid (Clontech, Palo Alto, CA, USA) while
the luciferase expression plasmid used for transfec-
tion studies in HepG2 cells was a 5650 bp plasmid
coding for the luciferase gene under the control of
the human CMV immediate early promoter^en-
hancer element. Both plasmid constructs were pro-
vided by Dr. P. Tam (Inex Pharmaceuticals, Burna-
by, BC, Canada). Phosphorothioate ODNs were
synthesized at the Nucleic Acid and Protein Synthe-
sis unit at the University of British Columbia (Van-
couver, BC, Canada) with the following sequences:
luciferase antisense ODN (5P-GTCTTCCATGG-
TGGCTTTACCAACAG-3P), control luciferase (re-
verse sequence) ODN (5P-GACAACCATTTCGGT-
GGTACCTTCTG-3P), ODN and 5P-£uorescein-
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labeled ODN used for uptake and microscopy stud-
ies (5P-CCGTGGTCATGCTCC-3P). The lipids di-
oleoylphosphatidylethanolamine (DOPE) and 1,2-di-
oleoyl-glycero-3-phosphoethanolamine-N-(lissamine
rhodamine L sulfonyl) (RhoPE) were obtained from
Northern Lipids (Vancouver, BC, Canada) and
Avanti Polar Lipids (Alabaster, AL, USA), respec-
tively.
2.2. Cationic and PEG-lipids
Dioleyldimethylammonium chloride (DODAC)
and PEG-lipids were synthesized by Dr. S. An-
sell and Z. Wang, respectively, at Inex Pharmaceuti-
cals.
2.3. Cell culture
HepG2 cells were cultured in MEM containing
10% FBS. HeLa cells were grown in DMEM con-
taining 10% FBS, 100 units/ml penicillin, 0.1 mg/ml
streptomycin and 200 Wg/ml G418.
2.4. HeLa-luciferase (HeLa-Luc) stable cell line
HeLa cells were stably transfected with the tIRE-
SNeo plasmid containing the luciferase reporter gene
using complexes made with DODAC/DOPE vesicles.
Cells were exposed to vesicle/DNA complexes for 48
h, at which time the medium was replaced with nor-
mal growth medium containing 500 Wg/ml G418
(Gibco). Antibiotic resistant colonies were expanded
and selected for high luciferase protein expression
after 2 weeks.
2.5. Vesicles
Lipids were mixed in chloroform and dried under
a stream of nitrogen gas. The thin lipid ¢lm was
lyophilized under vacuum for s 2 h to remove resid-
ual solvent before hydration with distilled water to
form multilamellar vesicles. The vesicles were freeze-
thawed ¢ve times utilizing liquid nitrogen and warm
water cycles and then extruded through 0.1 Wm pore
size polycarbonate ¢lters using an Extruder (Lipex
Biomembranes, Vancouver, BC, Canada) to generate
large unilamellar vesicles [9]. Vesicles were made
composed of DODAC/DOPE (1:1, mole ratio), DO-
DAC/DOPE/PEG-lipid (47.5:47.5:5, mole ratio),
DODAC/DOPE/RhoPE (49.5:49.5:1, mole ratio)
and DODAC/DOPE/PEG-lipid/RhoPE (47:47:5:1,
mole ratio).
2.6. Formulation of lipid/DNA complexes
Vesicle/plasmid or vesicle/ODN complexes were
prepared in polystyrene tubes 10^20 min before use
by quickly mixing and vortexing an equal volume of
the DODAC-containing vesicles with an equal vol-
ume of plasmid DNA or ODN in distilled water. The
relative proportions of lipid and nucleic acid are ex-
pressed in terms of a +/3 charge ratio calculated by
assuming a mean molecular weight for a phospho-
diester (DNA) and phosphorothioate (ODN) nucle-
otide sodium salt of 325 and 357, respectively. One
nucleotide base carries one negative charge while
DODAC has one positive charge. An optimum
+/3 charge ratio of 1 and 1.5 was used for complexes
made with DNA and ODN, respectively.
2.7. Luciferase transfection of HepG2 cells
HepG2 cells, plated overnight in 96-well plates at
2U104 cells per well, were incubated with 50 Wl of
lipid/DNA complexes (0.5 Wg DNA/well) and 150 Wl
of normal growth medium. The cells were incubated
at 37‡C with 5% CO2 for 24 h and then washed twice
with 150 Wl phosphate bu¡ered saline (PBS). After
removing the PBS, the plate was stored at 370‡C for
up to 2 weeks before being assayed.
2.8. Luciferase assay
The cells were thawed and solubilized by addition
of 40 Wl of lysis bu¡er (0.1% Triton X-100) and the
plate was shaken at room temperature for 15 min.
An aliquot of the cell lysate (20 Wl) was removed and
assayed for luciferase expression using a commercial
kit (Promega, Madison, WI, USA). Fluorescent sig-
nal was quanti¢ed using a ML 3000 microtiter plate
luminometer. The remainder of the cell lysate in the
well was used for assaying cellular content using
a BCA protein assay (Sigma, Oakville, ON, Cana-
da).
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2.9. Uptake of RhoPE-labeled vesicles and
FITC-ODN by HepG2 cells incubated with
lipid/DNA complexes
HepG2 cells, plated overnight in 96-well plates at
5U104 cells per well, were incubated with 40 Wl of
the lipid/DNA complexes in 120 Wl of medium (¢nal
ODN concentration of 0.02 ng/Wl or 280 nM). After
24 h, the cells were washed with PBS and lysed with
0.6% Triton X-100. Uptake of the £uorescent labels
was quanti¢ed using a Biolumin 960 £uorescence
plate reader (Molecular Dynamics, Sunnyvale, CA,
USA) at excitation and emission wavelengths of 485
and 520 nm, respectively, for FITC-ODN (ODN la-
beled with £uorescein at the 5P end) and 520 and 595
nm for RhoPE. Vesicle and ODN uptake were de-
termined separately using RhoPE-labeled complexes
or lipid/FITC-ODN complexes to minimize £uores-
cence overlap of the £uorophores. The results are
presented as a percentage of what was added to
each well taking into account background light scat-
tering from untreated cells.
2.10. Antisense activity as measured by luciferase
expression in HeLa-Luc cells
A 50 Wl aliquot (3.6 ng/Wl or 500 nM ODN ¢nal)
was added to 150 Wl of fresh medium and incubated
with HeLa-Luc cells (plated overnight in 96-well
plates at 1.5U104 cells per well). After 24 h, lucifer-
ase protein expression was assayed as outlined
above.
2.11. Fluorescent microscopy
HepG2 cells, plated overnight on glass coverslips
in 24-well plates at 2U105 cells per well, were ex-
posed to RhoPE-labeled lipid/FITC-ODN complexes
(¢nal concentration of 2 ng/Wl ODN). At various
times, unbound complexes were removed, cells
washed with PBS and ¢xed in PBS, pH 7.4, contain-
ing 3% paraformaldehyde. The coverslips were
mounted on glass slides and visualized either using
a Bio-Rad 600 confocal microscope or a Nikon Dia-
phot 300 epi£uorescence microscope.
3. Results
3.1. E¡ect of PEG-lipids on DODAC/DOPE
mediated transfection of HepG2 cells
Lipid/DNA complexes prepared by mixing unila-
mellar DODAC/DOPE vesicles with plasmid DNA
transfect a wide variety of cells in vitro [10,22,23].
For this study HepG2 cells were transfected with a
luciferase reporter gene using lipid/DNA complexes
prepared at a +/3 charge ratio of 1, which was pre-
viously determined to be optimal for these cells and
plasmid batch (data not shown). After 24 h extensive
luciferase expression was measured in cells treated
with PEG-free lipid/DNA complexes (Fig. 1). How-
ever, incorporating 5 mole% PEG-lipid into the com-
plexes profoundly inhibited transfection. In one set
of experiments distearoylphosphatidylethanolamine
(DSPE) PEG-lipids were employed in which a termi-
nal galactose group was attached to the PEG (Gal-
PEG-DSPE) in an attempt to enhance the cellular
uptake of complexes by endocytosis via galactose
receptors [32,13,43]. The presence of a large PEG
moiety (M.Wt. 3400) completely blocked transfection
(Fig. 1). Reducing the size of the PEG head group to
Fig. 1. E¡ect of PEG-lipid conjugates on luciferase transfection
mediated by DODAC/DOPE/PEG vesicles in HepG2 cells. DO-
DAC/DOPE (1:1, mole ratio) or DODAC/DOPE/PEG-lipid
(47.5:47.5:5, mole ratio) vesicles were mixed with 0.5 Wg of
pINEXL002 and the resulting lipid/DNA complexes (50 Wl)
were incubated with the HepG2 cells, plated in 96-well plates at
2U104 cells/well in the presence of 0.2 ml medium. After 24 h,
the cells were assayed for luciferase protein activity as outlined
in Section 2. Each data point represents an average of four
samples þ S.D.
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1450 molecular weight resulted in a small but mea-
surable level of luciferase expression while a further
reduction in PEG molecular weight to 220 restored
transfection to the same levels achieved using PEG-
free lipid/DNA complexes. Another series of PEG-
lipids (but minus galactose) were synthesized using
ceramide rather than DSPE as the lipid core (PEG-
Cer). Both DSPE and ceramide based PEG-lipids
have been shown previously to exhibit similar steric
barrier properties when associated with liposomes
[40]. Galactose was not incorporated because we
did not ¢nd a signi¢cant enhancement in uptake by
targeting the galactose receptor (data not shown).
For this series of PEG-lipids the PEG head group
was kept constant at a M.Wt. of 2000, a size known
to act as an e¡ective steric barrier [40], but the hy-
drophobicity of the anchor was varied by changing
the length of the amide chain linked to the 2-position
of the sphingosine backbone. Complete inhibition of
active gene transfer was observed for 1-O-[2P-(g-
methoxypolyethyleneglycol)succinoyl]-2-N-myristoyl-
sphingosine (PEG(2000)-CerC20), in which the amide
chain was 20 carbons long, whereas a small but sig-
ni¢cant increase in gene expression was measurable
when the length of the chain was progressively de-
creased to C14 and C8 (Fig. 1).
3.2. E¡ect of PEG-lipids in DODAC/DOPE mediated
delivery of antisense into HeLa cells
HeLa cells stably transfected with the luciferase
gene (HeLa-Luc cells) were also used to measure
the e¡ect of PEG-lipids on the activity of an anti-
sense oligonucleotide delivered by cationic lipid
vesicles. Two antisense ODN were employed, a phos-
phorothioate (PS) 26-mer ODN complementary to
the 5P start region of the luciferase gene and a con-
trol ODN with the same base composition but in
reverse sequence. The mechanism of action for phos-
phorothioate antisense ODN is mainly through the
activation of RNase H, which recognizes PS ODN/
RNA heterodimers as a substrate and cleaves the
RNA strand [2]. Therefore successful delivery of ac-
tive ODN to the cytoplasm and/or nucleus and sub-
sequent binding to target mRNA should reduce the
concentration of luciferase mRNA and subsequently
luciferase protein compared to controls.
Lipid/ODN complexes, free ODN or cationic
vesicles alone were incubated with HeLa-Luc cells
in the presence of 10% serum. Under these condi-
tions range-¢nding studies with lipid/ODN com-
plexes indicated that the maximum antisense e¡ect
occurs over a broad range of +/3 charge ratios,
from 1.0 to 2.5 (data not shown). Consequently,
these experiments were conducted using complexes
Fig. 2. Antisense activity mediated by cationic vesicle/ODN
complexes in HeLa cells stably transfected with a luciferase
gene. (A) ODNs either complementary to the 5P start sequence
of the luciferase gene (hatched white bars) or containing a re-
verse sequence (black bars) were mixed with DODAC/DOPE
(1:1, mole ratio) or DODAC/DOPE/PEG-lipid (47.5:47.5:5,
mole ratio) vesicles. An aliquot of the vesicle/ODN complexes
(50 Wl, 350 nM ODN) was incubated with HeLa-Luc cells
(plated in 96-well plates at 1.5U104 cells/well) in 0.2 ml of me-
dium. After 24 h, luciferase activity was assayed as outlined in
Section 2. The white bars represent cells which were exposed to
the vesicles alone while the gray bar are untreated cells.
(B) The di¡erence in luciferase expression between HeLa cells
exposed to the active luciferase antisense ODN and the reverse
ODN was calculated from the data shown in A. Each data
point represents an average of four samples þ S.D.
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made at a +/3 charge ratio of 1.5. After 24 h, the
cells were assayed for luciferase activity as outlined
in Section 2. Neither cationic vesicles alone nor free
ODN had a signi¢cant e¡ect on luciferase activity
compared to untreated cells (Fig. 2A). However, ex-
posure of the cells to lipid/ODN complexes made
with the active antisense ODN resulted in a signi¢-
cant reduction in luciferase expression relative to un-
treated cells. Interestingly, successful delivery of the
control ODN sequence had a stimulatory e¡ect on
luciferase expression. Cytoplasmic delivery of PS
ODN has been shown to non-speci¢cally stimulate
gene expression for a variety of target proteins [4]
and increased mRNA levels are commonly observed
when using antisense targeting the luciferase gene
(T. Woolf, personal communication). The e¡ect
is thought to arise through the non-speci¢c bind-
ing of transcription factors with the PS backbone
[2].
In Fig. 2B the data are expressed as the di¡erence
in luciferase expression between cells exposed to the
antisense and control ODN. When plotted this way a
pattern of activity is seen more clearly as being
similar to that observed for plasmid transfection
(Fig. 1). Incorporating 5 mole% PEG(2000)-CerC20
reduced the relative expression of luciferase by
s 80%. However, this level of inhibition was signi¢-
cantly reduced as the amide chain length at the 2-
position of the ceramide backbone was decreased
from C20 through C14 to C8 (Fig. 2B).
3.3. Binding of lipid/ODN complexes to cells and
endocytosis
One explanation for the inhibitory e¡ect of PEG-
lipids on DNA transfer could be that cellular uptake
of the complexes is reduced through steric hindrance
of binding to the cell surface. In order to address this
a £uorescently labeled ODN was used to determine if
nucleic acid uptake (binding and endocytosis) medi-
ated by DODAC/DOPE complexes is a¡ected by the
presence of PEG-lipids. Complexes were prepared
with FITC-ODN and incubated with HepG2 cells.
At various times, unbound lipid/ODN complexes
were removed, the cells washed with PBS and cellular
£uorescence measured after lysis with Triton X-100.
Over a 21 h time course only minor di¡erences in
cellular uptake of FITC-ODN mediated by PEG-
free complexes or complexes containing 5 mole% 1-
O-[2P-(g-methoxypolyethyleneglycol)succinoyl]-2-N-
octanoylsphingosine (PEG(2000)-CerC8), 1-O-[2P-(g-
Fig. 3. Uptake of RhoPE-labeled vesicles and FITC-ODN
by HepG2 cells incubated with vesicle/ODN complexes. (A)
DODAC/DOPE (b), DODAC/DOPE/PEG(2000)-CerC8 (a),
DODAC/DOPE/PEG(2000)-CerC14 (F) or DODAC/DOPE/
PEG(2000)-CerC20 (E) was mixed with plasmid DNA as in Fig.
1. An aliquot (40 Wl) of the lipid/ODN complexes was incu-
bated with the HepG2 cells, plated overnight in 96-well plates
at 5U104 cells/well, in the presence of 120 Wl of MEM contain-
ing 10% FBS. After 24 h, the cells were washed with PBS and
lysed with PBS containing 0.6% Triton X-100. Uptake of the
£uorescent labels was quanti¢ed using a £uorescence plate read-
er (Biolumin 960, Molecular Dynamics) at excitation and emis-
sion wavelengths of 485 and 520 nm, respectively. (B) In a par-
allel experiment, vesicle uptake by HepG2 cells incubated with
the lipid/ODN complexes was determined using vesicles labeled
with 1 mole% RhoPE. Each data point represents an average
of four samples þ S.D.
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methoxypolyethyleneglycol)succinoyl]-2-N-myristoyl-
sphingosine (PEG(2000)-CerC14), or PEG(2000)-Cer-
C20 were measured (Fig. 3A). Similar results were
obtained in a parallel experiment in which cellular
uptake of the lipid carrier was measured using
RhoPE as a £uorescent lipid marker. Vesicles con-
taining 1 mole% RhoPE were employed to prepare
complexes with ODN and incubated with HepG2
cells as above (Fig. 3B). As with the previous study
only relatively minor di¡erences between samples
could be detected over the 21 h time course.
3.4. Endocytosis of lipid/FITC-ODN complexes
visualized by confocal microscopy
The uptake levels measured in the previous section
are a combination of the amount bound to the plas-
ma membrane as well as that endocytosed, therefore
confocal microscopy was used to assess whether or
not PEG-lipids inhibit internalization. HepG2 cells
were exposed for 6 h to lipid/ODN complexes con-
taining FITC-ODN and RhoPE then ¢xed in para-
formaldehyde and visualized by confocal microscopy
(Fig. 4). The distribution pattern of the FITC signal
indicates that the ODN has been internalized, as
FITC £uorescence is observed throughout the cell
with the majority of the signal concentrated in the
nucleus (Fig. 4A, arrows). The outline of the nucleus
is more clearly seen using the rhodamine ¢lter set
(Fig. 4B). Here the lipid label is also intracellular
but remains outside the nucleus, which is a character-
istic of cationic lipid mediated delivery of ODN
[18,23]. When the endosome is successfully disrupted
by lipids the ODN subsequently released into the
cytoplasm rapidly accumulate in the nucleus, where-
as the lipids appear to remain associated with the
endosome/lysosome compartment. When PEG(2000)-
CerC20 is incorporated into the labeled complexes
both the FITC (Fig. 4C) and RhoPE (Fig. 4D) are
internalized as before but now both signals remain
perinuclear and nuclear £uorescence is not observed
at any time. This is consistent with the earlier results
in HeLa-Luc cells showing that PEG(2000)-CerC20
severely inhibits antisense activity.
Fig. 4. Internalization of DODAC/DOPE/ODN and DODAC/DOPE/PEG(2000)-CerC20/ODN complexes in HepG2 cells as visualized
by confocal microscopy. DODAC/DOPE/RhoPE/FITC-ODN complexes (500 nM ODN ¢nal) were incubated with HepG2 cells in the
presence of 10% FBS-MEM. After 6 h, the cells were ¢xed in 3% paraformaldehyde and visualized by confocal microscopy. FITC-
ODN £uorescence is localized intracellularly and is concentrated in what appears to be the cell nucleus (A, arrows). The RhoPE-la-
beled vesicles are also internalized but, in contrast to the ODN, remain perinuclear (B). Cells incubated with DODAC/DOPE/RhoPE/
PEG(2000)-CerC20/FITC-ODN complexes also display internalization of the FITC-ODN (C) and RhoPE-labeled vesicles (D) but both
labels remain perinuclear.
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Fig. 5. Nuclear delivery of FITC-ODN mediated by DODAC/DOPE/RhoPE/PEG vesicles in HepG2 cells after 1.5 h incubation. A
£uorescein-labeled ODN was mixed with various cationic vesicles containing 1% RhoPE and an aliquot of the lipid/ODN complexes
(400 nM ODN ¢nal) was incubated with HepG2 cells in MEM containing 10% FBS. After 1.5 h, the lipid/ODN complexes were re-
moved and replaced with fresh medium before being visualized either through a £uorescein ¢lter set (left panels) or by phase contrast
(right panel). The vesicles used were: (A,E) DODAC/DOPE/RhoPE (49.5:49.5:1, mole ratio); (B,F) DODAC/DOPE/RhoPE/
PEG(2000)-CerC8 (47:47:1:5, mole ratio); (C,G) DODAC/DOPE/RhoPE/PEG(2000)-CerC14 (47:47:1:5, mole ratio); (D,H) DODAC/
DOPE/RhoPE/PEG(2000)-CerC20 (47:47:1:5, mole ratio). Arrows indicate FITC signal that is localized in the cell nucleus.
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Fig. 6. Nuclear delivery of FITC-ODN mediated by DODAC/DOPE/RhoPE/PEG vesicles in HepG2 cells after 6 h incubation. Cells
exposed to lipid/ODN complexes as indicated in Fig. 5 were visualized either through a £uorescein ¢lter set (left panels) or by phase
contrast (right panel) after 6 h. (A,E) DODAC/DOPE/RhoPE (49.5:49.5:1, mole ratio); (B,F) DODAC/DOPE/RhoPE/PEG(2000)-
CerC8 (47:47:1:5, mole ratio); (C,G) DODAC/DOPE/RhoPE/PEG(2000)-CerC14 ; (D,H) DODAC/DOPE/RhoPE/PEG(2000)-CerC20
(47:47:1:5, mole ratio).
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3.5. Inhibition of endosome disruption by PEG-lipids
Our data suggest that incorporating PEG-lipids
into lipid/DNA complexes does not prevent their in-
ternalization by endocytosis but interferes with dis-
ruption of the endosome and therefore release of
ODN into the cytoplasm. The appearance of FITC-
labeled nuclei within 2^4 h of lipid-based delivery is
an excellent indicator of successful cytoplasmic deliv-
ery and can be used to compare the delivery e⁄cien-
cies of di¡erent formulations [23]. Furthermore,
there is a good correlation between the appearance
of nuclear £uorescence and antisense speci¢c activity
as measured by decreasing levels of target mRNA
[18]. In the following experiment, nuclear delivery
of FITC-ODN to HepG2 cells was used to determine
whether reducing the size of the hydrophobic anchor
associated with PEG(2000)-Cer lipids correlated with
the antisense activity data presented for HeLa-Luc
cells (see Fig. 2).
Lipid/DNA complexes, labeled with FITC-ODN
and RhoPE, were incubated with HepG2 cells in
the presence of 10% serum and after 1.5 h the cells
were washed and examined by £uorescence micros-
copy. Even after this relatively short incubation peri-
od, the nuclei of cells incubated with PEG-free com-
plexes emit an intense green £uorescence resulting
from the accumulation of FITC-ODN (Fig. 5A). Lo-
calization to the nuclei was con¢rmed by examining
the same ¢eld under phase contrast (Fig. 5E). The
outline of the cell nucleus is more clearly seen in Fig.
5F (arrow), correlating to the shape of the green
cellular £uorescence (Fig. 5B, arrow). The yellow
punctuate £uorescence seen shining through the
FITC £uorescence ¢lter set is due to intense signal
from rhodamine. The location of the RhoPE label is
consistent with the lipid dissociating from the ODN
and remaining localized in the endosomal pathway.
Incorporation of PEG(2000)-CerC8 appears to
slightly reduce the number of cells with nuclear £uo-
rescence (Fig. 5B), while PEG(2000)-CerC14 (Fig.
5C) and PEG(2000)-CerC20 (Fig. 5D) are clearly in-
hibitory. FITC £uorescence is not observed in these
latter samples as the ODN remains localized within
endosomes with RhoPE-labeled lipid and thus FITC
£uorescence is quenched through resonance energy
transfer and low pH environment [44,23]. After 6 h
cells incubated with formulations containing
PEG(2000)-CerC8 (Fig. 6B) and PEG(2000)-CerC14
(Fig. 6C) exhibit similar nuclear £uorescence to cells
incubated with PEG-free complexes. However, nu-
clear £uorescence was not visible in cells incubated
with lipid/DNA complexes containing PEG(2000)-
CerC20 (Fig. 6D). A similar trend was seen when
the size of the PEG head group was varied. Vesicles
containing 5 mole% Gal-PEG(220)-DSPE mediated
nuclear delivery of FITC-ODN similar to that ob-
served for PEG-free DODAC/DOPE vesicles but in-
clusion of Gal-PEG(3400)-DSPE prevented endoso-
mal release even after a 48 h incubation (data not
shown).
4. Discussion
In this study we show that the presence of 5 mole%
PEG-lipid conjugates, a typical concentration used
in vivo [20,31,32], can interfere with the ability of
DODAC/DOPE vesicles to mediate the intracellular
delivery of DNA. Interestingly, PEG-lipid did not
substantially inhibit uptake of the lipid/DNA com-
plexes (Fig. 3). Instead it interfered with the ability
of the lipid complexes to disrupt the endosomal
membrane in a manner that was dependent on
both the acyl chain length of the lipid anchor and
the molecular weight of the PEG moiety.
In general, lipid-based particles that exhibit a net
surface charge (positive or negative) bind more
avidly to cells in culture than neutral particles, pre-
sumably via electrostatic interactions with charged
proteins and carbohydrates at the cell surface
[27,28]. The studies described here were all conducted
in the presence of plasma proteins, which are also
known to coat charged lipid membranes with more
protein-to-lipid (w/mol) than neutral lipid mem-
branes [30]. Consequently, we assume the lipid/
DNA complexes employed here bind to the cell sur-
face through electrostatic forces and/or plasma pro-
tein mediated interactions with receptors.
PEG-lipids are commonly employed in liposome
and other lipid-based drug delivery systems to pro-
vide a steric barrier at the particle surface which in-
hibits protein binding and therefore opsonization in
vivo [38,30]. PEG is a £exible hydrophilic polymer
that extends approx. 3^5 nm from the membrane
surface, depending on the number of PEG monomers
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and membrane concentration of PEG-lipid [38,26].
The hydrophilic coating provided by PEG also inhib-
its the close apposition and fusion of liposomes with
other membranes [8,3]. The fact that 5 mole% PEG
had no signi¢cant e¡ect on the binding and subse-
quent endocytosis of lipid/DNA complexes by
HepG2 cells in this study (Fig. 3) was therefore sur-
prising. It is interesting to note, however, that Sem-
ple et al. [30] found that the presence of 10%
PEG(2000)-CerC20 in DODAC/DOPE (1:1, mole ra-
tio) vesicles reduced the level of protein binding sig-
ni¢cantly compared to PEG-free DODAC/DOPE
vesicles, but bound serum protein levels were still
about 4-fold more than measured for equivalent neu-
tral vesicles. Furthermore, Harvie et al. [6] recently
concluded that PEG-induced inhibition of transfec-
tion in their lipid-based gene transfer system did not
correlate with a reduction in endocytosis. These re-
sults indicate that the steric barrier does not neces-
sarily prevent electrostatic interactions taking place
with the vesicle surface.
After binding and uptake, the next phase in the
DNA delivery process is to induce su⁄cient pertur-
bation of the endosomal membrane to enable the
release of DNA into the cytoplasm [45]. This requires
lipid mixing to occur between lipid/DNA complexes
and the intracellular membrane [39,42,23]. The inter-
membrane di¡usion of long chain phospholipids or
glycolipids through an aqueous space is generally
negligible as a result of the large increase in hydro-
phobic free energy associated with forming the de-
sorption transition state [34,33]. However, the elec-
trostatic interaction between cationic lipid vesicles
and anionic membranes is strong enough to bring
the oppositely charged membrane surfaces into su⁄-
ciently close apposition to make desorption energeti-
cally more favorable [35,16,36,28]. This phenomen-
on, in combination with the membrane disruptive
properties of DOPE, is in part why cationic lipid/
DNA complexes have proven to be so e¡ective at
delivering polynucleic acids into the cytoplasm. Our
data show that PEG-lipids inhibit this process (Figs.
4^6), consistent with studies of Mori et al. which
indicate that incorporation of PEG-lipids in cationic
vesicles will inhibit their lipid mixing with anionic
membranes [21]. Furthermore, if the PEG-moiety is
kept constant the extent of the inhibition correlates
with the rate at which the PEG-lipid can desorb and
di¡use away from the complex [41,40,33,8]. On the
other hand, if the hydrophobic anchor is kept con-
stant inhibition correlates with the capacity of the
hydrophilic PEG group to act as a steric barrier [25].
These data are consistent with the following inter-
pretations. In the presence of a stable and e¡ective
steric barrier imposed by PEG-lipids with acyl
chains s 14 carbons long or PEG head groups
s 220 M.Wt. (Figs. 1 and 2) the contact between
complexes and endosomal membrane is not su⁄cient
to enable lipid exchange and subsequent membrane
disruption. Alternatively, lipid exchange may occur
but the PEG-lipid stabilizes the membrane structure
by preventing the induction of non-bilayer structures
[7]. However, the latter is not consistent with the
report of Holland et al. demonstrating that a stable
steric barrier prevents vesicles^vesicle fusion as mea-
sured by a lipid mixing assay [8]. PEG-lipids with
short acyl chains are known to rapidly di¡use away
from liposomal membranes in the presence of a suit-
able ‘sink’ such as other membranes or lipoproteins
[34,33,8,41]. Therefore complexes containing these
lipids may have reduced PEG concentrations by the
time they become endocytosed. It is also possible
that the di¡usible PEGs exchange into the endoso-
mal membrane after endocytosis, therefore rendering
the lipid/DNA particle more capable of membrane
perturbation in a time dependent manner. Such a
mechanism would be consistent with the data dis-
cussed below.
The inhibitory e¡ect of PEG(2000)-CerC14 and
-CerC8 on gene transfection by complexes appears
to be more signi¢cant than for antisense transfer
(Figs. 1 and 2), although both show the same trend.
This may be related to the relative stabilities of phos-
phodiester DNA compared to phosphorothioate
DNA [2]. As the residence time for DNA inside the
endosome/lysosome pathway increases, due to the
inhibitory e¡ects of PEG-lipid on its release into
the cytoplasm, it will become more vulnerable to
nuclease attack, especially as cationic lipid complexes
only partially protect DNA from nucleases [41]. The
natural phosphodiester backbone of the luciferase
plasmid will be rapidly degraded compared to the
relatively nuclease resistant phosphorothioate back-
bone of the antisense. The PEG-induced delay in
DNA release is clearly seen for the FITC-labeled
antisense in Fig. 5. In the absence of PEG or in
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the presence of PEG(2000)-CerC8, £uorescent nuclei
are observed after 1.5 h. At this time point very little
nuclear £uorescence is observed for complexes con-
taining PEG(2000)-CerC14 or -CerC20. However, the
same level of nuclear £uorescence is achieved by
complexes containing PEG(2000)-CerC14 after 6 h
(Fig. 6), whereas even after 2 days (data not shown)
complexes containing PEG(2000)-CerC20 were un-
able to deliver su⁄cient concentrations of FITC-
ODN into the cell to produce visibly £uorescent
nuclei. These data indicate that the complexes are
undergoing a time dependent change in the endo-
some, possibly involving di¡usion of exchangeable
PEG-lipid into the organelle membrane. Subsequent
or concurrent events, such as displacement of the
cationic lipid from the ODN through interaction
with anionic endosomal membrane lipids, have also
been postulated to be required for endosomal release
of the ODN [44].
Recently, Meyer et al. [19] demonstrated that even
2 mole% PEG-DSPE was su⁄cient to block the cy-
toplasmic delivery of £uorescent antisense into SK-
BR-3 cells in vitro. The presence of intracellular
(punctate) £uorescence indicates that uptake of lip-
id/ODN complexes occurred but that endosomal re-
lease was inhibited. What was most interesting about
this study, however, was that the addition of 1%
lipid-conjugated anti-HER2 F(abP) to the complexes
resulted in nuclear £uorescence [19], despite only a
modest 2-fold increase in uptake due to targeting cell
surface HER2. The authors suggest that in the pres-
ence of antibody, the lipid/ODN complexes are traf-
¢cked di¡erently and enter a pathway in which the
endosomes are more permissive to the escape of
ODN into the cytoplasm. Similar observations have
been made for liposomes containing protein antigens
[29].
In conclusion, the results presented here demon-
strate that a stable steric barrier ¢rmly anchored in
the membrane of cationic lipid/DNA particles inhib-
its DNA transfer out of the endosome/lysosome
pathway probably by reducing the insertion of per-
turbing lipids into the organelle membrane. This
highlights the di⁄culties associated with using steric
barrier lipids either to control aggregation during
self-assembly of lipid/DNA particles or for reducing
their rapid clearance and aggregation following in-
travenous administration. Optimizing the desorption
rate of PEG-lipids may be one approach that can be
used to overcome their inhibitory e¡ects on intracel-
lular delivery of plasmids and other polynucleic acids
such as antisense, ribozymes and immunostimulatory
oligonucleotides.
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